To market the drug solanezumab, Eli Lilly & Co. may need to do another study to confirm the findings, said Maria Carrillo, a vice president of medical and scientific relations at the Alzheimer’s Association. Photographer: Victor J. Blue/Bloomberg
To market the drug solanezumab, Eli Lilly & Co. may need to do another study to confirm the findings, said Maria Carrillo, a vice president of medical and scientific relations at the Alzheimer’s Association. Photographer: Victor J. Blue/Bloomberg
%7Cutmccn%3D(direct)%7Cutmcmd%3D(none);&utmn=724321959&utmp=%2Fphoto%2F2012-10-08%2Flilly-alzheimer-s-drug-slows-mental-decline-study-finds&utmhn=10.248.179.13&utmac=UA-11413116-12&utmhid=178956542)